Piper Sandler raised the firm’s price target on Quest Diagnostics to $145 from $140 and keeps a Neutral rating on the shares. The firm cites the company’s recent earnings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics upgraded to Buy from Hold at Jefferies
- Quest Diagnostics price target lowered to $125 from $140 at Deutsche Bank
- Quest Diagnostics price target lowered to $145 from $150 at Truist
- Quest Diagnostics price target lowered to $150 from $165 at Mizuho
- Quest Diagnostics price target lowered to $136 from $140 at Baird
